home / stock / ebs / ebs news


EBS News and Press, Emergent Biosolutions Inc. From 04/05/21

Stock Information

Company Name: Emergent Biosolutions Inc.
Stock Symbol: EBS
Market: NYSE
Website: emergentbiosolutions.com

Menu

EBS EBS Quote EBS Short EBS News EBS Articles EBS Message Board
Get EBS Alerts

News, Short Squeeze, Breakout and More Instantly...

EBS - Johnson & Johnson Given Control of Emergent BioSolutions Factory That Botched Its Coronavirus Vaccine

The U.S. government has given Johnson & Johnson (NYSE: JNJ) control of a Baltimore production facility operated by Emergent BioSolutions (NYSE: EBS) . The move is the latest development in a controversy over Emergent's production of Johnson & Johnson's coronaviru...

EBS - Emergent Bio receives modified task order for expansion of JNJ's COVID-19 vaccine

Emergent BioSolutions (EBS) has received a contract modification from BARDA to increase the original task order by $23M.The additional sum will be used to purchase biologics manufacturing equipment specific to Johnson & Johnson’s (JNJ) COVID-19 vaccine for the potential expansion o...

EBS - Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & John

HHS has increased Emergent’s task order by $23 million to purchase additional biologics manufacturing equipment Reaffirms 2021 financial guidance GAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Compa...

EBS - HHS puts J&J in charge of Emergent BioSolutions plant behind vaccine foul-up - NYT

The Biden administration has put Johnson & Johnson (JNJ) in charge of the Emergent BioSolutions (EBS) beleaguered Baltimore plant that ruined 15M doses of the company's COVID-19 vaccine, according to a report in The New York Times.The newspaper says HHS made the move to avoid further foul...

EBS - Emergent COVID-19 immunoglobulin therapy fails in phase 3

An experimental COVID-19 treatment from Emergent BioSolutions (EBS) failed in a phase 3 trial.Emergent's experimental SARS-CoV-2 immunoglobulin  therapy (COVID-HIG), which was combined with Gilead's (GILD) Veklury (remdesivir), did not provide any benefit when compared to standard o...

EBS - Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19

GAITHERSBURG, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) for the treatment of hospitalized patients with COVID-19. The Phase 3 Inpa...

EBS - Why Emergent BioSolutions Crashed Today

Emergent BioSolutions (NYSE: EBS) was a dog of a stock Thursday, plummeting to close down by over 13%. This followed news that the company apparently erred in the production process of Johnson & Johnson 's (NYSE: JNJ) recently authorized coronavirus vaccine. Johnson ...

EBS - NVVE, UXIN, MVIS and XSPA among midday movers

Gainers: AeroCentury (ACY) +235%.Liberty TripAdvisor (LTRPB) +106%.Uxin (UXIN) +53%.Universe Pharmaceuticals (UPC) +36%.Applied Molecular Transport (AMTI) +31%.Euro Tech Holdings (CLWT) +26%.PLBY Group (PLBY) +25%.Nuvve (NVVE) +24%.Moxian (MOXC) +18%.Sonoma Pharmaceuticals (SNOA) +1...

EBS - Emergent's plant implicated in vaccine mix-up had issues cited by FDA in 2020: AP

Emergent BioSolutions ([[EBS]] -12.9%) is trading sharply lower today in reaction to yesterday’s New York Times report over the accidental vaccine contamination at its Baltimore plant manufacturing two coronavirus vaccines developed by Johnson & Johnson ([[JNJ]]...

EBS - Wall Street Breakfast: Eyes On A Rare Payrolls Day

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Eyes on a rare payrolls dayThe tech stock rally looks to keep going with Nasdaq futures solidly higher at the open, but the broader market is more cautions...

Previous 10 Next 10